ArticleActa pharmaceutica Sinica. B2022
One-step synthesis of site-specific antibody-drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates.
Open access · diamondAbstract read
In one paragraph
Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Hinge-region Cys-to-Ser mutation enables homogeneous DAR6 anti-c-Met biparatopic ADCs with tolerable O-glycosylation.Antibody therapeutics · 2026Article
- Generation of DAR1 Glycosite-Specific Antibody-Drug Conjugates Using DisacLink Technology.Chembiochem : a European journal of chemical biology · 2026Article
- Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination.Acta pharmacologica Sinica · 2026Article
- Article
- Rational Design, Synthesis, and Systematic Evaluation of Redox-Responsive SN-38 Prodrugs for Selective Activation in Hypoxic Tumor Microenvironments.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Efficient Preparation of Homogenous Antibody Conjugates via Glycosite-Specific Transglycosylation Enabled by Readily Available Glycosyl Donors.Angewandte Chemie (International ed. in English) · 2026Article
- Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations.mAbs · 2025Review
- A review of conjugation technologies for antibody drug conjugates.Antibody therapeutics · 2025Review
- Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.RSC medicinal chemistry · 2025Review
- Synthesis of site-specific Fab-drug conjugates using ADP-ribosyl cyclases.Protein science : a publication of the Protein Society · 2024Article
- Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy.Pharmaceutical research · 2024Review
- Bioorthogonal microglia-inspired mesenchymal stem cell bioengineering system creates livable niches for enhancing ischemic stroke recoveryActa pharmaceutica Sinica. B · 2024Article
- Evaluation of Two Chemoenzymatic Glycan Remodeling Approaches to Generate Site-Specific Antibody-Drug Conjugates.Antibodies (Basel, Switzerland) · 2023Article
- Modulating antibody effector functions by Fc glycoengineering.Biotechnology advances · 2023Review
- Site-Specific Antibody Conjugation Using Modified BisectedBioconjugate chemistry · 2023Article
- Polymeric biomaterial-inspired cell surface modulation for the development of novel anticancer therapeutics.Biomaterials research · 2023Review
- Mechanism of antibody-specific deglycosylation and immune evasion by Streptococcal IgG-specific endoglycosidases.Nature communications · 2023Article
- Modular Chemical Construction of IgG-like Mono- and Bispecific Synthetic Antibodies (SynAbs).ACS central science · 2023Article
- Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins.Molecules (Basel, Switzerland) · 2023Review
- Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-Mediated Antibody-Drug Conjugation.Bioconjugate chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Wei ShiCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China.
Wanzhen LiSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Jianxin ZhangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Tiehai LiCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China.
Yakai SongCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China.
Yue ZengCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China.
Qian DongCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China.
Zeng LinCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China.
Likun GongCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China.
Shuquan FanSchool of Life Science, Liaocheng University, Liaocheng 252059, China.
Feng TangCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China.
Wei HuangCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai 201203, China.
Chinese Academy of Sciences · CNNanjing University of Chinese Medicine · CNLiaocheng University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycosite-specific antibody‒drug conjugatess (gsADCs), harnessing Asn297
Indexed as
ENGaseLacNAcOne-step assemblyPotent in vivo efficacySite-specific ADCs
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.